New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
13:43 EDTREGNRegeneron risk/reward favorable, says RBC Capital
RBC Capital views Regeneron's risk/reward as favorable at current levels given REGN727 data expected in 2013 and 2014.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:51 EDTREGNBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:31 EDTREGNRegeneron price target raised to $462 from $418 at BofA/Merrill
Subscribe for More Information
November 20, 2014
07:47 EDTREGNRegeneron price target raised to $450 from $390 at Brean Capital
Subscribe for More Information
05:22 EDTREGNRegeneron, Sanofi receive FDA Breakthrough Therapy designation in AD
Subscribe for More Information
November 19, 2014
08:17 EDTREGNRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
November 18, 2014
05:43 EDTREGNRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use